Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer.
10.4046/trd.2006.60.2.151
- Author:
Sung Woo YANG
1
;
Pyoung Rak CHOI
;
Hong Jun YOU
;
Jin Gu KIM
;
Chul Ho OAK
;
Tae Won JANG
;
Maan Hong JUNG
Author Information
1. Department of Internal Medicine, Kosin University, College of Medicine, Korea. jungmh@ns.kosinmed.or.kr
- Publication Type:Original Article
- Keywords:
ERCC1;
MAGE;
Non-small cell lung cancer;
Sputum
- MeSH:
Carcinogens;
Carcinoma, Non-Small-Cell Lung*;
Cisplatin;
Complement System Proteins;
DNA Repair;
Drug Therapy*;
Humans;
Sputum*;
Taxoids
- From:Tuberculosis and Respiratory Diseases
2006;60(2):151-159
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Excision repair cross complementing gene 1 (ERCC1) not only has a protective role against carcinogens, but plays an important role in cisplatin-resistance via the repair of cisplatin-DNA adducts. This study investigated the association between the ERCC1 expression levels in sputum and survival after cisplatin-based chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). METHODS: Using the sputum collected from 67 inoperable (stage IIIa-IV) NSCLC patients treated with either taxanes (33 cases) or gemcitabine (34 cases) plus cisplatin, the relative expression levels of ERCC1 and the expression of the tumor specific antigen, MAGE, were examined by the quantitative RT-PCR and RT-PCR, respectively. The response and survival were compared with the relative level of ERCC1 or MAGE expression and the treatment modality. RESULTS: In the sputum, ERCC1 and MAGE was detected in 74.6% and 40.2% of patients, respectively. Using the median ERCC1 level, the patients were classified as having high or low ERCC1 expression. The median overall survival (MST) was significantly longer in patients with a high ERCC1 expression level than those with a low expression level (84 weeks vs. 44 weeks respectively, P=0.017). In the taxene-based treatment group, the MST was longer than the gemcitabine group (79 weeks vs. 47 weeks, respectively, P=0.03). The levels of ERCC1 were significantly higher in patients who were MAGE-positive (P=0.003). In the MAGE-negative patients, the MST was longer in the high ERCC1 group (103 weeks vs. 43 weeks, P=0.008), but not in the MAGE-positive patients (62 weeks vs. 44 weeks, P=0.348). CONCLUSION: ERCC1 expression in the sputum can be a prognostic factor for survival after chemotherapy in patients with inoperable NSCLC.
